The marker α-3 in the Boston Heart HDL Map Test is one of the specific subpopulations of high-density lipoprotein (HDL) particles measured to assess cardiovascular disease (CVD) risk. HDL particles, often referred to as "good cholesterol," play a crucial role in transporting cholesterol from the arteries to the liver for removal from the body. Among the various HDL subpopulations, α-3 HDL is particularly significant because it is involved in reverse cholesterol transport, a process that helps reduce cholesterol buildup in the arteries and thus lowers the risk of atherosclerosis and heart disease.
The α-3 marker specifically measures the concentration of apoA-I protein in this HDL subclass. ApoA-I is the main protein component of HDL and is essential for its cholesterol-clearing functions. Elevated levels of α-3 HDL are generally associated with a lower risk of CVD because they indicate a robust capacity for reverse cholesterol transport. Conversely, low levels of α-3 HDL may suggest a diminished ability to remove cholesterol from the bloodstream, potentially leading to plaque buildup in the arteries and increased CVD risk.
By quantifying α-3 HDL levels, the Boston Heart HDL Map Test provides detailed insights into a patient’s cardiovascular health. This information can guide healthcare providers in developing personalized treatment plans, including lifestyle changes and medications to improve HDL functionality and reduce CVD risk. Understanding and monitoring α-3 HDL levels can be a crucial step in proactive heart health management, helping to prevent heart attacks, strokes, and other cardiovascular events.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.